Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any retinitis pigmentosa in which the cause of the disease is a mutation in the PRPF8 gene.
Features include very common findings: Nyctalopia; and common findings: Cystoid macular edema and Subcapsular cataract. 11 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 5 | Optic disc drusen, Cystoid macular edema, Retinal degeneration |
PRPF8 function has not been fully characterized.
Retinitis pigmentosa 13 is associated with mutations in the PRPF8 gene on chromosome 17.
Genetic testing for PRPF8 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for retinitis pigmentosa 13 has been reported in the published literature.
Phenotype severity distribution: 1 very common feature, 2 common features.
No clinical trials have been registered for retinitis pigmentosa 13.
42 publications have been identified in PubMed for retinitis pigmentosa 13. Research spans Basic Science / Preclinical (48%), Case Report / Case Series (17%), and Epidemiology / Natural History (17%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 20 | 48% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 11:55 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
1 |
Bone spicule pigmentation of the retina |
Age of onset: adolescence.
7 |
17% |
Disease patterns and progression | 7 | 17% |
New treatment approaches | 5 | 12% |
Testing and diagnosis research | 2 | 5% |
Clinical study results | 1 | 2% |
Wang A (2026). [PMID: 41776480](https://pubmed.ncbi.nlm.nih.gov/41776480/). *BMC Ophthalmol*. [Case Report / Case Series]
Wentling M (2026). [PMID: 41572507](https://pubmed.ncbi.nlm.nih.gov/41572507/). *Adv Sci (Weinh)*. [Basic Science / Preclinical]
Sun X (2026). [PMID: 41533919](https://pubmed.ncbi.nlm.nih.gov/41533919/). *Invest Ophthalmol Vis Sci*. [Basic Science / Preclinical]
Beaulieu C (2026). [PMID: 41954904](https://pubmed.ncbi.nlm.nih.gov/41954904/). *JAMA Ophthalmol*. [Epidemiology / Natural History]
Valenzano R (2026). [PMID: 41751772](https://pubmed.ncbi.nlm.nih.gov/41751772/). *Int J Mol Sci*. [Basic Science / Preclinical]
Quinodoz M (2026). [PMID: 41513982](https://pubmed.ncbi.nlm.nih.gov/41513982/). *Nat Genet*. [Basic Science / Preclinical]
Mauriac SA (2026). [PMID: 40994011](https://pubmed.ncbi.nlm.nih.gov/40994011/). *Mol Ther*. [Gene Therapy / Novel Therapeutics]
Zimmann F (2026). [PMID: 41731009](https://pubmed.ncbi.nlm.nih.gov/41731009/). *Sci Rep*. [Basic Science / Preclinical]
Kemal RA (2025). [PMID: 40264708](https://pubmed.ncbi.nlm.nih.gov/40264708/). *Front Cell Dev Biol*. [Basic Science / Preclinical]
Salameh M (2025). [PMID: 40674075](https://pubmed.ncbi.nlm.nih.gov/40674075/). *JAMA Ophthalmol*. [Basic Science / Preclinical]